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Abstract
Introduction: Proximal spinal muscular atrophy (SMA) is a common autosomal
recessively inherited neuromuscular disorder. It is caused by homozygous
absence of the survival motor neuron 1 (SMN1) gene. SMN2, which modulates
the severity of the disease, represents a major target for therapy. The aim of
this study was to investigate whether SMN2 expression can be increased by
caffeic acid, chlorogenic acid and curcumin, which are designed by modifications
of the carboxylic acid class of histone deacetylase (HDAC) inhibitors. 
Material and methods: Using quantitative real-time PCR, we analysed the levels
of full-length SMN2 and Δ7SMN2 mRNA. We performed LDH cytotoxicity assay
to analyse whether SMN2 activating concentrations of caffeic acid, chlorogenic
acid and curcumin were cytotoxic to fibroblasts.
Results: We found that caffeic acid and curcumin were more efficient than
chlorogenic acid and increased full-length SMN2 mRNA levels 1.5 and 1.7-fold,
respectively. Δ7SMN2 mRNA levels were measured to investigate alternative
splicing of exon 7. We also found that cytotoxicity was not observed at SMN2
activating concentrations.
Conclusions: Our data suggest that carboxylic acid derivatives including phenolic
structure and symmetry could be a good candidate for SMA treatment.
Key words: histone deacetylase inhibitors, SMN2 gene, therapy.
Introduction
Autosomal recessive spinal muscular atrophy (SMA) is a leading genetic
cause of childhood mortality. Patients develop symmetrical, proximal
weakness resulting from neurogenic muscle atrophy. The disease is
characterized by selective loss of large α motor neurons in the anterior
horn of the spinal cord. Clinically, childhood-onset SMA is classified into
three groups (type I: severe, type II: intermediate, type III: mild) according
to age of onset and severity [1, 2]. All forms of SMA are caused by the
homozygous deletion of the telomeric copy of the survival motor neuron
(SMN1) gene on chromosome 5q13 [3-5], which codes the survival motor
neuron (SMN) protein [6]. A second gene, centromeric copy of the SMN
gene (SMN2) is also located at the same chromosomal region [3]. Because
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of a silent mutation (C to T) at position + 6 in exon 7,
an exonic splicing enhancer (ESE) is destroyed and
exon 7 skipping occurs in SMN2 pre-mRNA [7]. In
contrast to SMN1, SMN2 only produces 10% full-
length transcripts (FL-SMN2). Ninety percent of
SMN2 transcripts lack exon 7 (Δ7SMN2) and cannot
compensate for the loss of SMN1 [8]. 
SMN2 is considered as the major target for
a potential SMA therapy. Increasing SMN2 trans  -
cription and changing its splicing pattern are the
most effective strategies [9]. Several histone
deacetylase (HDAC) inhibitors which increase the
expression of the SMN2 gene have been described
[10-16]. The HDAC inhibitors stimulate acetylation
of histones which can relax chromatin structure
and enable binding of transcriptional machinery to
target genes [17]. They are known to change the
expression of 7-10% of genes [18]; but, how they
activate SMN2 expression remains unknown.
Histone deacetylase inhibitors consist of a metal
binding moiety, a capping group and a linker [19].
They are divided into hydroxamates, cyclic
tetrapeptides, benzamides, electrophilic ketones
and carboxylic acids [20]. The carboxylic acid class
such as sodium butyrate, phenylbutyrate and
valproic acid is the first investigated HDAC inhibitor
group in the treatment of SMA. Their effect has
been tested in SMA mouse models and treatment
improved motor abilities and reduced neuro  -
degeneration [21]. 
There are limited structure activity data for
carboxylic acids. Therefore, in our previous study
we developed new carboxylic acid derivatives by
rational design and molecular modifications were
made to the functional group, capping group and
linker. In addition to the rational design approach,
molecular docking which predicts inhibitor activity
was used. After interpreting the results obtained
from rational design and molecular docking tools,
we found that among carboxylic acid derivatives,
caffeic acid, chlorogenic acid and curcumin have
the highest HDAC inhibition activity in a fluorimetric
assay [22]. Since the SMN2 gene is present in all
patients, it acts as a modifier gene. Therefore
activating the SMN2 gene is a promising approach
in SMA therapeutics. In this study, we investigated
the effect of caffeic acid, chlorogenic acid and
curcumin, which have HDAC inhibition activity, on
SMN2 gene expression. 
Material and methods
Cell culture and treatment
Human fibroblast cell line (Coriell Cell Repository,
GM03813, 3 years old SMA type I) were cultured in
DMEM with 10% FCS, 1% penicillin/streptomycin,
1% L-glutamine. 5 × 105 cells were treated with
caffeic acid (20 μM, 50 μM, 100 μM), chlorogenic
acid (20 μM, 50 μM, 100 μM) and curcumin 
(12.5 μM, 20 μM, 25 μM, 50 μM, 100 μM) for 24 h.
The concentrations used for the three derivatives
were chosen according to the activity of known
carboxylic acids [23, 24]. For each experiment
complete medium was added as a control. 
Quantitative analysis of FL-SMN2 and SMN2Δ7
transcripts
Total RNA was isolated by RNeasy Mini Kit
(Qiagen) and the absorbance was detected by
NanoDrop ND-1000. 450 ng of RNA was converted
to cDNA by Quantitect RT (Qiagen). Real-time 
RT-PCR was performed in triplicate by the iQ5 Real-
Time PCR Detection System (Biorad Lab). 25 μl real-
time RT-PCR reaction contained 0.096 μM probe,
0.9 μM of each primer and 12.5 μl of TaqMan
Universal Master Mix (Applied Biosystems). The
conditions were 10 min at 95°C, and 40 cycles of 
15 s at 95°C and 1 min at 60°C. The sequences of
primers and TaqMan probes were published by
Andreassi et al. [11]. The levels of SMN2 transcripts
were quantified by 2–ΔΔCt method and normalized
to GAPDH and β-actin (Applied Biosystems). The
untreated sample was used as a calibrator. The
experiments were repeated twice. 
Cytotoxicity assay
Cytotoxicity of compounds was measured using
LDH Cytotoxicity Assay Kit II (Biovision). 4 × 104 cells
were plated in triplicate and incubated at 5% CO2,
37°C for 24 h. Untreated cells were used as low
control and cells treated with lysis solution served
as high control. Cytotoxicity was determined after
24 h of compound treatment. Following 30 min of
incubation at room temperature, absorbance at 
450 nm (reference wavelength was 650 nm) was
measured to determine LDH activity. Percentage of
cytotoxicity was calculated as the ratio of test
sample’s absorbance to high control’s absorbance. 
Results 
To determine the effect of carboxylic acid
derivatives on SMN2 expression and splicing, the
SMA fibroblast cell line was treated with caffeic acid
(20 μM, 50 μM, 100 μM), chlorogenic acid (20 μM,
50 μM, 100 μM) and curcumin (12.5 μM, 20 μM, 
25 μM, 50 μM, 100 μM) for 24 h. The levels of SMN2
mRNA were determined by real-time RT-PCR. 
All three compounds showed an increase in 
FL-SMN2 mRNA levels dose dependently (Figure 1).
The analysis showed that 20 μM caffeic acid
increased FL-SMN2 1.5-fold (Figure 2A). After
treatment with chlorogenic acid FL-SMN2 showed
a minor increase at 50 μM which was 1.3-fold.
However, this increase was not statistically
significant compared to the untreated sample
Carboxylic acids in the treatment of SMA232 Arch Med Sci 2, April / 2011
(Figure 2B). Interestingly, curcumin, which showed
a 1.7-fold significant increase in FL-SMN2 mRNA
levels, was regarded as the most efficient among
all three derivatives (Figure 2C). 
To investigate whether caffeic acid, chlorogenic
acid and curcumin influence alternative splicing of
exon 7, we also studied the effect of three
compounds on the synthesis of Δ7SMN2 mRNA
levels. In experiments with caffeic acid, no increase
in Δ7SMN2 mRNA levels were observed. The ratio
of FL to Δ7 mRNA levels increased by almost 2-fold
between 0 μM and 50 μM (Figure 2A). The
treatment with chlorogenic acid resulted in an
increase in only Δ7SMN2 mRNA levels, suggesting
that chlorogenic acid may work through a different
mechanism for SMN2 exon 7 inclusion (Figure 2B).
We found that curcumin increased both FL and
Δ7SMN2 mRNA levels at 12.5 μM and 20 μM. The
FL/Δ7 mRNA level remained constant between 
12.5 μM and 20 μM but increased between 50 μM
and 100 μM (Figure 2C). 
We performed an LDH cytotoxicity assay to
analyse whether SMN2 activating concentrations
(20-50 μM) of caffeic acid, chlorogenic acid and
curcumin were cytotoxic to fibroblasts. The
absorbance of the samples is shown in Figure 3. We
found that cytotoxic effects were not detectable
and cell viability was 100%. 
Discussion
Recently HDAC inhibitors have been shown to
play a role in the treatment of some genetic
diseases and also have neuroprotective properties
[25]. Therefore they are regarded as candidates for
neurodegenerative diseases such as SMA. The
disease severity is changed according to functional
FL mRNA produced from the SMN2 gene. Therefore
increasing SMN2 gene expression has an important
role in therapy. The HDAC inhibitors could increase
SMN2 gene expression either by directly increasing
acetylation at the promoter or changing the
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Figure 1. Effect of carboxylic acid derivatives on 
FL-SMN2 transcript level. SMA fibroblast cell line was
treated with chlorogenic acid (50 μM), caffeic acid
(20 μM) and curcumin (20 μM) for 24 h. Error bars
represent standard deviation
*p < 0.05 shows significant difference in treated compared
to untreated
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Figure 2. Real-time RT-PCR analysis of FL and Δ7SMN2
transcripts following treatment with caffeic acid (A),
chlorogenic acid (B), curcumin (C) at increasing
concentrations for 24 h. Error bars represent standard
deviation
*p < 0.05 shows significant difference in treated compared to
untreated
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Figure 3. LDH cytotoxicity assay of chlorogenic acid 
(50 μM), caffeic acid (20 μM) and curcumin (20 μM)
on SMA fibroblast cell line. Cytotoxicity was calculated
at SMN2 activating concentrations according to the
manufacturer’s protocols. Low control: 0.380, high
control: 1.87. Error bars represent standard error
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acetylation of a transcription factor that indirectly
binds the promoter. Alternatively, HDAC inhibition
could change the expression of splicing proteins
that increase exon 7 inclusion [12]. 
The HDAC inhibitors have a common pharma  -
cophore which consists of three components. The
metal-binding functional group coordinates binding
to the Zn++. The hydrocarbon linker fills out the
narrow tunnel, and the capping group interacts with
the amino acids near the active site [19]. The design
of the new inhibitors is based on the modification
of the functional group, capping group and the
linker. Carboxylic acid derivatives were modified by
insertion of hydroxyl and/or carboxylic groups into
the alkyl chain or phenyl ring. As we reported
previously, after screening a panel of carboxylic acid
derivatives, caffeic acid, chlorogenic acid and
curcumin were shown to have the highest HDAC
inhibition activity [22]. In our current study, we
analysed whether these three compounds produced
increased amounts of FL-SMN2 transcript. 
Caffeic acid is a polyphenol that occurs in fruits,
wine and coffee. It has been shown to have
antioxidant, antiinflammatory, antimetastatic and
anti-tumour effects [26]. Real-time RT-PCR results
showed that FL transcript levels were increased 
1.5-fold after caffeic acid treatment. Previous studies
indicated that among carboxylic acids, phenyl  -
butyrate and valproic acid increased FL transcript
levels between 1.3-1.6 and 1.2-1.5-fold, respectively,
in SMA fibroblasts, which is consistent with our
data [11-13]. We also found that Δ7SMN2 transcript
levels were reduced and the ratio of FL to Δ7 mRNA
levels was increased at some concentrations. The
increase in FL to Δ7 ratio indicates that caffeic acid
may reverse the SMN2 splicing pattern and prevent
exon 7 skipping. Enhanced expression of splicing
factors that stimulate exon 7 inclusion could be an
explanation for this reversion.
By keeping the 4-vinylbenzene-1,2-diol main
structure of caffeic acid, two caffeic acid derivatives
were chosen. The first derivative, which is
chlorogenic acid, is an ester of caffeic acid. We
detected a 1.3-fold minor increase in FL-SMN2
transcript levels, which was not statistically
significant. It may be speculated that the loss of
activity is probably the reason for steric hindrance
of the polyfunctional cyclohexane ring.
The second derivative, curcumin, the twin
structure of caffeic acid, is found in the Indian curry
spice turmeric and shows anti-inflammatory and
antioxidant activities [27, 28]. It has been shown
that curcumin inhibits proliferation of cells and
induces cell cycle arrest or apoptosis in various
types of cancers [29]. Cell signal pathways and
protein kinases including NF-κB, AKT, mitogen-
activated protein kinase, STAT, COX-2 and LOX have
been reported as targets for curcumin [30-32]. The
mechanism of curcumin in SMA treatment has not
been determined but studies showed that multi  -
ple activities of curcumin are involved in the
neuroprotective effect of the compound [33].
Following treatment, we found that curcumin
showed the highest increase in FL-SMN2 transcript
levels among all compounds, which was detected
as 1.7-fold. The reason for increased activity may be
symmetry in the curcumin molecule. On the other
hand, the level of FL-SMN2 at 50 μM, and the level
of FL-SMN2 and Δ7SMN2 at 100 μM were
decreased. In the context of enzyme kinetics this
decrease may suggest that saturation is achieved
gradually between HDAC enzyme and its ligand
curcumin. 
We conclude that the molecular structure of
curcumin is the one best fitting the HDAC enzyme
active site. Therefore it may be speculated that two
phenolic hydroxyl groups and a free carboxylic acid
group are not crucial for good interaction with the
HDAC enzyme since caffeic acid and chlorogenic
acid have one of these two groups. But probably
a p-hydroxy group is necessary for hydrogen bonds
and an enon group for reversible electrostatic
interactions with HDAC enzymes. 
Similar to our results, Sakla et al. [24] also
treated GM03813 cell lines with polyphenols and
examined them by RT-PCR. They reported that
compounds increase exon 7 inclusion of SMN2
transcripts. We also detected an increase in
Δ7SMN2 transcript levels and the ratio of FL to 
Δ7 mRNA levels remained constant. This increase
in both isoforms may be explained by SMN2
promoter activation. However, detecting an increase
in FL/Δ7 mRNA levels between 50 μM and 100 μM
treatment suggests that curcumin may also prevent
exon 7 skipping. Our data show that curcumin
increases FL-SMN2 transcript by not only activating
the promoter, but also splicing. 
On the basis of these observations, further
experiments are being planned on caffeic acid and
curcumin to investigate their effect on SMN2
protein. Western blot analysis combined with real-
time RT-PCR results will provide more information
about the mechanism of the compounds’ effect on
SMN2 expression. 
In recent years, phenolic compounds have
become popular for protection against degenerative
diseases including SMA [33]. The phenolic structure
and replication of the molecule, as demonstrated
in curcumin, can be one of the strategies to design
novel HDAC inhibitors in the treatment of SMA.
In conclusion, in this study, we found that among
carboxylic acid derivatives, caffeic acid and
curcumin increase the level of FL-SMN2 mRNA in
SMA fibroblasts, indicating that they can be
potential candidates in the treatment of SMA.
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Future studies will aim for rational design by
keeping the phenolic structure and symmetry of
HDAC inhibitors.
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